Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa

Background. Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson’s disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients. Methods. Data were collected from several p...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Parkinson's disease Ročník 2020; číslo 2020; s. 1 - 11
Hlavní autoři:	Antonini, Angelo, Benesh, Janet, Kukreja, Pavnit, Ijacu, Horia, Bergmann, Lars, Boyd, James T., Poewe, Werner, Zadikoff, Cindy, Robieson, Weining Z.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Cairo, Egypt Hindawi Publishing Corporation 2020 Hindawi John Wiley & Sons, Inc Wiley
Témata:	Carbidopa Clinical trials Complications and side effects Datasets Demography Dopa Dopamine Dosage Double-blind studies Drug dosages Dyskinesia Intestine Levodopa Medical research Medicine, Experimental Movement disorders Neurodegenerative diseases Parkinson's disease Patients Pharmaceutical industry Polyneuropathy Quality of life Safety Safety and security measures Studies United States United States > US
ISSN:	2090-8083, 2042-0080
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!